Lenskart is an omnichannel eyewear retail company based in India (sources differ between Delhi and Gurgaon) that sells eyeglasses, sunglasses and contact lenses to consumers online and through its own stores.

This Startup Deep Dive explains what Lenskart does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Lenskart in Brief

• What it is: Lenskart is an Indian Eyewear omnichannel retail company.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Lenskart sells eyewear through online and company-owned stores in India and overseas.
• One report counts 2,067 stores in India and 656 overseas; earlier reports cited over 2,500 stores, of which 2,000 in India.
• June 2024: $200 million secondary from Temasek and Fidelity at about $5 billion valuation (reported).
• Funding: Around $1.08 billion (reported by one source).

Lenskart Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Lenskart?

Lenskart operates in the Eyewear omnichannel retail space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Lenskart.

• Lenskart sells eyewear through online and company-owned stores in India and overseas.
• One report counts 2,067 stores in India and 656 overseas; earlier reports cited over 2,500 stores, of which 2,000 in India.

The Origin Story of Lenskart

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Peyush Bansal, Neha Bansal, Amit Chaudhary, Sumeet Kapahi.
• Lenskart was founded in 2008 by Peyush Bansal, Neha Bansal, Amit Chaudhary and Sumeet Kapahi.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Eyewear omnichannel retail sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• June 2024: $200 million secondary from Temasek and Fidelity at about $5 billion valuation (reported).
• July 2025: filed for an IPO with a fresh issue of up to Rs 2,150 crore plus an offer for sale (reported).
• FY25: turned profitable with net profit of about Rs 297 crore versus loss of about Rs 10 crore in FY24.
• October 31 to November 4, 2025: IPO bidding with price band Rs 382-402, about Rs 7,278 crore issue size (reported).

Lenskart Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Pre-IPO: Fidelity marked its holding up to a $5.6 billion valuation (reported).
• IPO: fresh issue up to Rs 2,150 crore plus offer for sale by SoftBank, Kedaara Capital, Peyush Bansal and others (reported).
• SoftBank holds 15.04% and Abu Dhabi Investment Authority 12.45% (reported).

How Does Lenskart Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Sells eyewear via its own stores and online, with IPO fresh-issue funds earmarked for new company-owned stores, technology, brand marketing and possible acquisitions.

The Numbers: Lenskart Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY24: net loss about Rs 10.1 crore; revenue from operations about Rs 5,427.7 crore.
• FY25: net profit about Rs 297.3 crore; operating revenue Rs 6,652.5 crore per the DRHP, up 22.5% (another report gave Rs 6,415 crore, so figures differ).
• One analysis says about Rs 477 crore of FY25 profit came from non-operating items including a non-cash gain tied to the Owndays acquisition, putting adjusted operational profit closer to Rs 130 crore.

Market Opportunity for Lenskart

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Operates in the Indian and international eyewear retail market.

Technology and Product at Lenskart

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Core capability: Public detail on Lenskart’s technology stack is limited beyond company-stated descriptions.
• Assessment lens: clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

Team and Culture at Lenskart

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Peyush Bansal bought shares worth Rs 221.1 crore from existing shareholders ahead of the DRHP filing (reported).

Lenskart Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

• Direct competitors of Lenskart vary by product line; a verified rival comparison was not available from public sources.
• What to compare: Product readiness, pricing, customer base, funding runway and regulatory standing.

Risks and Challenges for Lenskart

• A large share of FY25 profit came from non-operating and non-cash items, according to one analysis.
• Reported revenue and store count figures differ across sources.
• Profitability is recent, following a loss in FY24.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Lenskart Growth Outlook: What to Watch

• IPO proceeds are planned for new company-owned stores, technology, brand marketing and possible acquisitions.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Lenskart can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Lenskart Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Lenskart

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Lenskart.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Lenskart

Studying a company in the Eyewear omnichannel retail space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Lenskart.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Lenskart as a Startup

• Customer clarity: Can Lenskart name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Lenskart is part of India’s growing Eyewear omnichannel retail ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Lenskart FAQs: Frequently Asked Questions

What is Lenskart?

Lenskart is an omnichannel eyewear retail company based in India (sources differ between Delhi and Gurgaon) that sells eyeglasses, sunglasses and contact lenses to consumers online and through its own stores. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Lenskart?

Lenskart was founded by Peyush Bansal, Neha Bansal, Amit Chaudhary, Sumeet Kapahi, and the company reports a founding year of 2008.

How much funding has Lenskart raised?

Around $1.08 billion (reported by one source). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Lenskart make money?

Lenskart earns revenue from its Eyewear omnichannel retail products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Lenskart?

Competitors of Lenskart depend on the specific product line. A verified comparison was not available, so see the evaluation checklist above.

What are the main risks for Lenskart?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Spacefields — IISc-incubated maker of solid rocket motors | HealthifyMe — HealthifyMe: from a 2012 Bengaluru app to a US push. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.